CareDx Announces First Commercial Sale of Olerup QTYPE

BRISBANE, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced the first commercial sale of its real-time q-PCR based HLA typing solution, Olerup QTYPE.

Olerup QTYPE for pre-transplant matching is completed within an hour and is a robust and easy to use alternative for rapid HLA typing. The rapid matching provided by Olerup QTYPE is an important performance differentiator for pre-transplant matching of organ donors and recipients. This new test brings several needed features to HLA labs, including speed and enhanced resolution.

“Following a convincing demonstration of Olerup QTYPE, we are excited to be the first center to order the new HLA typing kits,” says Cathi Murphey, HLA Director at Southwest Immunodiagnostics in San Antonio.

"We just launched our HLA typing solution at the ASHI conference in September 2016. The rapid commercial conversion demonstrates the compelling performance of Olerup QTYPE and the innovation embedded in the technology," stated Peter Maag, President and CEO of CareDx. "For CareDx, it is one step further along our road to provide novel diagnostic solutions to improve the care of transplant patients across pre- and post-transplant continuum."

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit:

CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs.

For more information, please visit:

Forward Looking Statements

This press release includes forward-looking statements, including statements relating to the commercialization of Olerup QTYPE and our ability to achieve commercial acceptance by clinicians and laboratories and revenue from this pre-transplant HLA matching test. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with achieving acceptance and revenue from a new pre-transplant HLA matching test, as well as many other risks discussed in the "Risk Factors" section of the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by CareDx with the SEC on March 29, 2016, the Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 filed by CareDx with the SEC on August 22, 2016 and the prospectus supplement filed with the SEC in September 22, 2016 and in other filings that we make with the SEC. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Investor Relations Contact Jamar Ismail, Vice President Westwicke Partners, LLC Investor Contact T: +1 415-513-1282 E:

Source:CareDx, Inc.